Developing patient-derived organoids to dissect the cellular & molecular mechanisms underpinning resolving and persistent forms of arthrofibrosis.

点击翻译按钮获取中文摘要

Arthrofibrosis is the pathologic stiffening of a joint due to exaggerated scar tissue formation, referred to as fibrosis. Frozen shoulder is a form of arthrofibrosis affecting the shoulder causing pain and disability through profound stiffening of the ligaments (capsule) that comprise the shoulder joint. Frozen shoulder is a unique form of arthrofibrosis because the condition successfully resolves over time. In contrast, fibrotic diseases of other joints persist, for example in the knee joint after patients undergo surgical knee replacement. This project will harness the knowledge of how fibrosis successfully resolves in the shoulder joint to understand why fibrosis in other joints such as the knee persist. We collected tissue samples from non-diseased comparator and frozen shoulder patients to generate an atlas of the cell types comprising the shoulder joint capsule. This atlas revealed that the shoulder capsule is comprised of cells called fibroblasts which have important functions in producing the proteins that comprise collagenous tissues like ligaments. We also identified macrophages, these are immune cells with important functions regulating inflammation and fibrosis which both occur during frozen shoulder. Using fibroblasts and macrophages derived from frozen shoulder patients, we discovered that crosstalk between resolving macrophages and fibroblasts dampen down inflammation and promote resolution of fibrosis, supporting our hypothesis that fibroblasts and macrophages are key cell types mediating fibrosis resolution. We also established that these cells implicated in resolving frozen shoulder are also present during foetal development, suggesting that the template to resolve fibrosis could be 'imprinted' during development. The biological processes that govern whether fibrosis resolves or persists remain to be identified. Knowledge from how fibrosis successfully resolves in the shoulder joint has the potential to inform how we could push persistent fibrotic diseases like knee arthrofibrosis towards a resolving trajectory. The overarching aim of this project is to identify the key cell types and molecules that drive persistent arthrofibrosis in the knee joint capsule and understand any differences relative to the shoulder joint. This project will create a cellular atlas of the human knee capsule during development, non-diseased and fibrotic states such that the cell populations can be directly compared with those in the shoulder joint where fibrosis resolves. The project will also utilise established tissue culture models comprised of patient-derived cells to confirm the cell types and molecules causal to fibrosis and resolution and test small molecules to moderate fibrosis. Murine and rodent animal models are frequently used to study joint diseases including osteoarthritis and arthrofibrosis. These animal models do not accurately recapitulate the equivalent human disease, some of these animal models cause considerable pain, discomfort and suffering. This project will utilise tissues and cells collected from human patients to replace the use of animal models to study osteoarthritis and arthrofibrosis. The project will pioneer the development of 3D models called organoids to study knee arthrofibrosis, utilising animal free products to construct the organoid models we will work with. Over time, as researchers adopt the approaches utilised in this project, it is anticipated that the findings from this research could further reduce the number of animals used to study fibrotic disease affecting the joint and beyond.This research will replace and reduce the requirement for animal arthrofibrosis models, identify new therapies to promote arthrofibrosis resolution, addressing an unmet clinical need for patients. Effective new arthrofibrosis treatments will reduce the development of co-morbidities associated with reduced mobility and reduce the healthcare financial burden for costs associated with joint replacement.